Item request has been placed!
×
Item request cannot be made.
×
Processing Request
HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- المصدر:
Publisher: BioMed Central Country of Publication: England NLM ID: 101251558 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-1596 (Electronic) Linking ISSN: 17461596 NLM ISO Abbreviation: Diagn Pathol Subsets: MEDLINE
- بيانات النشر:
Original Publication: [London] : BioMed Central, 2006-
- الموضوع:
- نبذة مختصرة :
Background: The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevance of HOXA9 and CD163 in PDAC progression.
Materials and Methods: Selected 98 PDAC and 98 adjacent non tumor tissues as a control group were immunostained with HOXA9 and CD163 antibodies.
Results: PDAC displayed highly significant higher HOXA9 staining intensity, percent and H score values than control group. HOXA9 staining of PDAC cases showed significant associations with poor prognostic indicators including larger tumor size, higher grade and advanced stage. PDAC showed highly significant differences regarding CD163 macrophage-specific staining intensity, percent and H score values than control group. CD163 showed significant higher expressions with larger tumor size, higher histological grade and advanced stage group. HOXA9 staining in PDAC showed highly significant direct correlations with CD163 positive macrophages. Follow up of PDAC cases revealed that high median H score of HOXA9 and CD163 were significantly associated with worse overall survival. CD163 was an independent prognostic marker of worse survival.
Conclusions: In conclusion, HOXA9 could potentiate PDAC progression by stimulating CD163 expressed TAM attraction in tumors. HOXA9 and CD163 could participate in PDAC therapy. HOXA9 and CD163 could be predictors of worse prognosis and shorter survival in PDAC.
(© 2024. The Author(s).)
- References:
J Clin Invest. 2010 May;120(5):1535-50. (PMID: 20389018)
Genom Data. 2015 May 19;5:54-8. (PMID: 26484224)
Cancers (Basel). 2021 Feb 14;13(4):. (PMID: 33672917)
Nat Rev Cancer. 2002 Jan;2(1):38-47. (PMID: 11902584)
PLoS One. 2011;6(7):e22052. (PMID: 21760952)
Cancer Res. 2018 Oct 1;78(19):5492-5503. (PMID: 30206177)
Diagn Pathol. 2014 Nov 29;9:221. (PMID: 25432701)
Leuk Res. 2015 Aug;39(8):874-82. (PMID: 26059450)
Gastroenterology. 2023 Apr;164(5):752-765. (PMID: 36804602)
Nat Commun. 2018 Apr 16;9(1):1480. (PMID: 29662084)
J Immunoassay Immunochem. 2024 Jul 3;45(4):342-361. (PMID: 38815282)
Ann Surg Oncol. 2018 Apr;25(4):845-847. (PMID: 28752469)
J Int Med Res. 2022 Nov;50(11):3000605221135864. (PMID: 36366735)
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. (PMID: 28117416)
Int J Mol Sci. 2022 Jun 18;23(12):. (PMID: 35743243)
Cancer Sci. 2012 Nov;103(11):2012-20. (PMID: 22931216)
Nat Rev Genet. 2008 May;9(5):329-40. (PMID: 18398419)
Am J Surg Pathol. 2005 Jun;29(6):724-33. (PMID: 15897739)
Am J Pathol. 2014 Jan;184(1):271-81. (PMID: 24332016)
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9920-5. (PMID: 23716660)
J Leukoc Biol. 2009 Nov;86(5):1065-73. (PMID: 19741157)
Immunol Rev. 2008 Apr;222:155-61. (PMID: 18364000)
Cancers (Basel). 2023 Feb 28;15(5):. (PMID: 36900335)
BMC Cancer. 2021 Mar 25;21(1):320. (PMID: 33765961)
Int J Mol Sci. 2019 Sep 11;20(18):. (PMID: 31514451)
Cancer Lett. 2017 Dec 1;410:68-81. (PMID: 28947139)
Front Oncol. 2021 Oct 29;11:771488. (PMID: 34778091)
World J Gastroenterol. 2000 Dec;6(6):805-811. (PMID: 11819700)
Cancer Manag Res. 2021 May 21;13:4147-4154. (PMID: 34045901)
- Contributed Indexing:
Keywords: CD163; HOXA9; Pancreatic ductal adenocarcinoma
- الرقم المعرف:
0 (CD163 antigen)
0 (Antigens, CD)
0 (Antigens, Differentiation, Myelomonocytic)
0 (homeobox protein HOXA9)
0 (Receptors, Cell Surface)
0 (Homeodomain Proteins)
0 (Biomarkers, Tumor)
- الموضوع:
Date Created: 20241027 Date Completed: 20241027 Latest Revision: 20241104
- الموضوع:
20241104
- الرقم المعرف:
PMC11514874
- الرقم المعرف:
10.1186/s13000-024-01563-5
- الرقم المعرف:
39462379
No Comments.